FDA Approves New Generic Mifepristone

The Food and Drug Administration (FDA) has greenlit a new generic version of Mifepristone as of Tuesday. This follows recent confirmations from the FDA about ongoing reviews of abortion drugs, specifically approving an application from Evita Solutions, LLC.

Evita Solutions stated, “We believe that everyone should have access to safe, affordable, high-quality, effective, and compassionate abortion services, irrespective of race, gender, age, sexuality, income, or location. We trust that individuals can make the best decisions for their own bodies.”

“Get this: FDA, which has just approved to distribute more abortion pills, doesn’t even believe there’s something like ‘women.’ From their website: ‘Evita Solutions believes *all people* should be safe, affordable, high quality and effective.” – Josh Hawley

The company’s application was submitted in 2021, as noted in the approval letter.

U.S. President Marjorie Dunnenfelser expressed disapproval, branding the FDA’s decision to expand access to abortion drugs as “reckless.” She argued that these drugs not only terminate pregnancies but also pose serious risks to women and minors, and undermine state laws designed to protect life.

Neither the FDA nor Evita Solutions offered immediate responses to requests for comment.

Meanwhile, Republican Senator Josh Hawley from Missouri shared his diminished trust in FDA leadership, emphasizing that “the FDA has just approved another chemical abortion drug” that he claims poses dangers to mothers.

In a letter dated September 19 to the Republican Attorney General, Robert F. Kennedy Jr. stated that the FDA is conducting a “unique review of evidence,” looking closely at drug safety and effectiveness based on real-world results.

RFK Jr. further remarked at a September hearing that the Biden administration appears to be “twisting data to downplay safety concerns” regarding Mifepristone.

This article is developing and will be updated as more information becomes available.